VRCA / Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 Weeks

Verrica focuses on dermatology therapeutics. The company just received approval for its first marketed product. more_horizontal

The U.S. Food and Drug Administration has approved Verrica Pharmaceuticals Inc's treatment of a viral skin disease in adults and children aged 2 years more_horizontal

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just i more_horizontal

Check these penny stocks out for your watchlist The post Hot Penny Stocks to Buy Now? 3 to Watch in Early July  appeared first on Penny Stocks to Buy more_horizontal

Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time. more_horizontal

Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was slapped with a third FDA rejection for YCANTH (VP-102) as general contract manufacturing organizatio more_horizontal

The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application for VP-102 for mo more_horizontal

The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to more_horizontal